

Mas-Related G Protein Coupled Receptor-X2: A Potential New Target for Modulating Mast Cell-Mediated Allergic and Inflammatory Diseases

Hydar Ali *

Department of Pathology, University of Pennsylvania School of Dental Medicine, USA

*Corresponding author: Ali H, Department of Pathology, University of Pennsylvania School of Dental Medicine, 240 South 40th Street, Philadelphia, 19104-6030, USA, Tel: 215-573-1993; Fax: 215-573-2050; E-mail: alih@upenn.edu

Received date: November 24, 2016; Accepted date: December 21, 2016; Published date: December 28, 2016

Copyright: © 2016 Ali H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Mast cells (MCs) are tissue resident immune cells that are best known for their roles in allergic and inflammatory diseases. In addition to the high affinity IgE receptor (FcεRI), MCs express numerous G protein coupled receptors (GPCRs), which are the most common targets of drug therapy. Neurokinin 1 receptor (NK-1R) is expressed on MCs and contributes to IgE and non-IgE-mediated responses in mice. Although NK-1R antagonists are highly effective in modulating experimental allergic and inflammatory responses in mice they lack efficacy in humans. This article reviews recent findings that demonstrate that while neuropeptides (NPs) activate murine MCs via NK-1R and Mas related G protein coupled receptor B2 (MrgprB2), they activate human MCs via Mas-related G protein coupled receptor X2 (MRGPRX2). Interestingly, conventional NK-1R antagonists have off-target activity against mouse MrgprB2 but not human MRGPRX2. These findings suggest that the failure to translate studies with NK-1R antagonists from *in vivo* mouse studies to the clinic likely reflects their lack of effect on human MRGPRX2. A unique feature of MRGPRX2 that distinguishes it from other GPCRs is that it is activated by a diverse group of ligands that include; neuropeptides, cysteine proteases, antimicrobial peptides and cationic proteins released from activated eosinophils and neutrophils. Thus, the development of small molecule MRGPRX2-specific antagonists or neutralizing antibodies may provide new targets for the treatment of MC-mediated allergic and inflammatory diseases.

Keywords: Mast cells; NK-1R; MrgprB2; MRGPRX2; Anaphylaxis; Asthma

Abbreviations FcεRI: High Affinity IgE Receptor; GPCR: G Protein Coupled Receptor; NK 1R: Neurokinin-1 Receptor; MrgprB2: Mas-related G Protein Coupled Receptor-B2, MRGPRX2: Mas-Related G Protein Coupled Receptor-X2; MC: Mast Cell; NP: Neuropeptide; HK-1: Hemokinin-1; SP: Substance P

Introduction

Mast cells are multifunctional immune cells that are found in all vascularized tissues throughout the body and contribute to vascular homeostasis, innate/adaptive immunity and wound healing [1]. MCs are, however, best known for their roles in allergic and inflammatory diseases such as anaphylaxis, food allergy, rhinitis, itch, urticaria, atopic dermatitis and asthma. In these conditions, activation of MCs via the cross-linking of high affinity IgE receptors (FcεRI) results in the release of preformed and newly synthesized mediators that contribute to signs and symptoms associated with allergic diseases.

Mast cells are generally classified into two types based on the protease content of their secretory granules [2,3]. In human, most MCs that are found in connective tissues such as the skin contain tryptase, chymase, carboxypeptidase and cathepsin and are known as MC_{TC}. In contrast, majority of MCs that are found in lung and gut express only tryptase and are known as MC_T. MCs also differ in their responses to endogenous and exogenous stimuli that promote degranulation. Thus, while both human MC subtypes are activated via the aggregation of FcεRI, only MC_{TC} respond to the neuropeptide substance P (SP) [4,5].

In mice, connective tissue MCs (CTMCs) resembles MC_{TC} while mucosal MCs (MMC) resemble MC_T [2,6]. Thus, murine CTMCs are found in the skin and MMC mature in the mucosal tissues such as the lung and gut. In addition, CTMCs are responsive to SP for degranulation but MMCs are not [7,8].

Substance P activates a variety of cell types including MCs via NK-1R and induces cutaneous vasodilation, plasma extravasation, flare and itch [8-12]. Accordingly, NK-1R antagonists effectively modulate experimental allergic and inflammatory responses in mice but they lack efficacy in clinical trials [13-17]. This article reviews recent findings which indicate that the reason for this difference may reflect differences in GPCR utilization between mouse and human MCs.

Roles of NK-1R on Neuropeptide and IgE-mediated Responses in Mouse MCs *In vitro* and Allergic Responses *In vivo*

It is generally accepted that MMCs such as murine bone marrow-derived cells (BMMC) do not express NK-1R [8]. However, BMMCs cultured in the presence of interleukin-4 (IL-4) and stem cell factor (SCF), which favor CTMC phenotype, results in the expression neurokinin 1 receptor (NK-1R). Furthermore, SP causes degranulation in these MCs, which is diminished by an NK-1R antagonist or in cells obtained from NK-1R^{-/-} mice [8]. Subcutaneous injection of SP in mice results in MC degranulation, which is followed by increased vascular permeability and marked infiltration of eosinophils and neutrophils [18,19]. These responses are absent in MC-deficient mice. However, when MC-deficiency is rescued with local engraftment of

cultured MCs, SP-induced responses are restored. These findings suggest that activation of NK-1R in murine MCs by SP results in increased vascular permeability and granulocyte recruitment *in vivo* (Figure 1A).

Substance P belongs to the tachykinin family of neurokinins and this family has recently been expanded to include hemokinin-1 (HK-1) [20]. Unlike SP, which is released from peripheral nerve endings of the sensory neurons, HK-1 is the only tachykinin peptide that is produced outside the neuronal tissue [20]. Sumpster et al. [21] recently demonstrated that FcεRI activation of murine BMMCs results in enhanced expression of both HK-1 and NK-1R without modifying SP levels. Furthermore, it was found that FcεRI-mediated MC degranulation and TNF/IL-6 production is substantially inhibited in NK-1R^{-/-} BMMCs when compared to wild-type MCs. These findings suggest that HK-1, via its action on NK-1R, acts as an autocrine/paracrine factor for FcεRI-mediated MC mediator release. As described below, HK-1/NK-1R axis has a profound impact on IgE-mediated experimental anaphylaxis and MC-dependent model of chronic atopic airway inflammation, an important feature of asthma [21].

Passive cutaneous anaphylaxis (PCA) is often used as an experimental model to study the mechanism of IgE-mediated type 1 hypersensitivity reactions. In this model, FcεRI-mediated histamine release from dermal MCs leads to increased vascular permeability, resulting in the formation of edema. This is followed by the release of TNF from MCs, which promotes the recruitment of neutrophils to the site of MC activation. Using MC-deficient mice reconstituted with wild-type, Tac1^{-/-} (HK-1) or NK-1R^{-/-} BMMCs, Sumpster et al. [21] showed that HK-1 and NK-1R expressed in murine MCs contribute to both early (edema) and late (neutrophil recruitment) phases of IgE-mediated PCA. In a mouse model of chronic allergic asthma, TNF derived from MCs contribute to Th2/Th17 cytokine production, airway hyperresponsiveness and inflammation [22-24]. Given that FcεRI-mediated TNF production is substantially inhibited in NK-1R^{-/-} BMMCs when compared to wild-type MCs raises the interesting possibility that this GPCR is important for the pathogenesis of allergic asthma. Indeed, absence of Tac1 or NK-1R in MCs leads to substantial decrease in eosinophil and neutrophil recruitment in a MC-dependent model of chronic asthma [21]. These findings suggest that HK-1 and its receptor NK-1R, which are upregulated following FcεRI activation, contribute to both anaphylaxis (Figure 1A) and chronic allergic asthma in mice (Figure 1B).

Role of MrgprB2 on SP-induced Degranulation of Murine MCs

In addition to NK-1R, murine CTMCs express Mas-related G protein coupled receptor B2 (MrgprB2) [25]. Generation of a transgenic mouse with td-Tomato reporter under the control of MrgprB2 promoter demonstrated that the expression of this receptor is restricted to CTMC in the skin, gut and trachea [25]. MrgprB2 mutant mice were generated by deleting a 4 base pair in the receptor's coding region, resulting in a frame shift mutation and early termination of the receptor (shortly after the first transmembrane domain). These mice have no defect in MC number and respond normally to IgE/FcεRI activation. However, peritoneal MCs from these mice show dramatic reduction in degranulation in response to SP *in vitro* and inflammation *in vivo* [25,26]. These findings suggest that NP-induced responses in murine MCs reflect the activation of two GPCRs; NK-1R and MrgprB2.




Figure 1: Proposed model for the roles of NK-1R and MrgprB2 on experimental neuropeptide and IgE-mediated responses in mice. SP released from nerve endings and HK-1 generated from MCs activate NK-1R and MrgprB2 on MCs to induce degranulation and TNF production. These mediators contribute to increased vascular permeability and leukocyte recruitment in (A) anaphylaxis and (B) chronic asthma. It is proposed that conventional NK-1R antagonists modulate these responses in mice by inhibiting both NK-1R and MrgprB2.


Conventional NK-1R Antagonists Block MrgprB2-mediated Responses in Mice but Lack Efficacy in Humans

Although it is currently unknown if HK-1 level is increased following the activation of human MCs, the expression of SP and NK-1R is upregulated in human asthmatic but not in normal individuals [13,14,27,28]. These findings suggest that NK-1R not only participates in experimental MC-mediated allergic responses, it also plays an important role in the human disease. Not surprisingly, a number of NK-1R antagonists have been developed to modulate allergic responses in animal models and for clinical trials in humans [13-16]. These antagonists are highly effective in animal models of allergic asthma and inflammation but lack efficacy in humans. Azimi et al. [17] recently showed that conventional NK-1R antagonists have off-target effect on the mouse MrgprB2. This suggests that the effectiveness of NK-1R antagonists in mice reflect not only their ability to block NK-1R but also their action against MrgprB2 (Figure 1). The striking failure to translate findings from animal models to the clinic suggests that there are important differences in the mechanisms via which NPs activate murine and human MCs.

Substance P Activates Human MC_{TC} via Mas-related G Protein Coupled Receptor-X2 (MRGPRX2) and Contributes to Chronic Urticaria

Similar to the situation in murine CTMCs, human skin MC_{TC} and human MC line (LAD2) express NK-1R and respond to SP for degranulation [29,30]. However, unlike the case with murine CTMCs, NK-1R antagonists have little or no effect on SP-induced response in human MCs [30]. The recent demonstration that MRGPRX2 is the human counterpart of mouse MrgprB2 raises the possibility that SP activates human MCs via this receptor. Tatemoto et al. [31] provided

the first demonstration that SP activates human cord blood-derived MCs via MRGPRX2 and this finding was later confirmed in studies with transfected RBL-2H3 cells and primary human skin MCs [1,30,32]. Fujisawa et al. [30] showed that skin MCs of patients with severe chronic urticaria express MRGPRX2 at higher level than the healthy subjects. Furthermore, SP causes degranulation and prostaglandin D₂ (PGD₂) generation in human skin MCs via MRGPRX2. Eosinophils accumulate in chronic urticaria lesions and their granules proteins (major basic protein, MBP and eosinophil peroxidase, EPO) cause MC degranulation via MRGPRX2 [30,33]. These findings suggest that activation of human MCs by SP via MRGPRX2 serves to initiate the wheal response. Furthermore, recruitment of eosinophils and the subsequent activation of MRGPRX2 by MBP and EPO contribute to the late phase of chronic urticaria (Figure 2A).



Possible Roles of MRGPRX2 in Severe Asthma and Asthma Exacerbation

Mast cells are important effector cells that orchestrate the development of airway hyperresponsiveness and inflammation in asthma via their close interaction with airway smooth muscle cells, T cells and leukocytes [34-36]. Microarray and PCR analyses showed that while high level of MRGPRX2 transcript is expressed in human skin MCs, only low level is present in lung MCs [30,37]. Mild allergic asthma is generally correlated with an increase in MC_T number in both submucosa and smooth muscle but severe asthma is dominated by the

presence of MC_{TC}, a MC subtype that expresses MRGPRX2 [30,38,39]. MC-derived mediators such as tryptase, histamine and cysteinyl leukotrienes interact with neurons to promote the release of neuropeptides such as SP [40]. The level of SP is elevated in the lung of asthmatics when compared normal lung [27,28]. Furthermore, SP causes degranulation of MCs obtained from bronchoalveolar lavage indicating a potential for MRGPRX2 in severe asthma [41]. Cathepsin S is a cysteine protease released from antigen-presenting cells and contributes to the pathogenesis of asthma [42-44]. Reddy et al. [45] recently showed that cathepsin S induces Ca²⁺ mobilization in HeLa cells expressing MRGPRX2. These findings suggest that both cathepsin S and SP contribute to the pathogenesis of severe asthma via the activation of MRGPRX2 in lung MC_{TC} (Figure 2B).

Respiratory infection by rhinoviruses causes asthma exacerbation in both children and adults. This is associated with MC degranulation and the recruitment of eosinophils and neutrophils to the airways [46-49]. Lung epithelial cells are the principal site of rhinovirus infection in both the upper and lower airways. Interestingly, rhinovirus induces the production of human β-defensins in bronchial epithelial cells [50,51], which activate human MCs via MRGPRX2 [1,52,53]. Neutrophils present in the lung of patients with rhinovirus-induced asthma also secrete the cathelicidin, LL-37, which activates human MC_{TC} via MRGPRX2 [52,54]. Thus, it is possible that MRGPRX2 expressed in human lung MC_{TC} contributes to rhinovirus-induced asthma exacerbation by responding to ligands generated from epithelial cells (β-defensins) [50,51], eosinophils (MBP and EPO) [30] and neutrophils (LL-37) (Figure 2B).

A Tripeptide NK-1R Antagonist Inhibits Human MC Activation via MRGPRX2

A unique feature of MRGPRX2 that distinguishes it from other GPCRs is that it is activated by multiple cationic ligands and may play important role in a variety of MC-mediated diseases (Figure 2) [1,25,30]. Thus, the development of small molecule MRGPRX2-specific antagonists or neutralizing antibodies may provide potential new therapeutic target for modulating MC-mediated allergic and inflammatory diseases. Azimi et al. [17] showed that a while conventional NK-1R antagonists block both NK-1R and MrgprB2, a tripeptide (QWF) NK-1R antagonist also has activity against human MRGPRX2. Thus, QWF inhibits SP-induced responses in HEK-293 cells stably expressing MRGPRX2 and a human MC line (LAD2) naturally expressing the receptor. These findings suggest that while NPs activate murine MCs via NK-1R and MrgprB2 they utilize MRGPRX2 for human MC activation. This difference likely explains why NK-1R antagonists modulate MC-mediated experimental allergic responses in mice but lack efficacy in humans. The tripeptide QWF is; however, unlikely to serve as an MRGPRX2-specific drug in the clinic because it lacks specificity for MRGPRX2 and it is rapidly metabolized in plasma [55]. Despite the potential limitations of QWF, its inhibitory effect on MRGPRX2-mediated MC degranulation provides a strong impetus for the development of specific small molecule MRGPRX2 antagonists or monoclonal antibodies for the treatment of MC-mediated diseases.

Conclusions and Future Direction

Neuropeptides activate murine MCs via NK-1R and MrgprB2 and human MCs via MRGPRX2. Conventional NK-1R antagonists have off target activity against mouse MrgprB2 but not human MRGPRX2. This

difference likely explains why conventional NK-1R antagonists modulate experimental allergic responses in mice but lack efficacy in humans [17]. It is noteworthy that MRGPRX2 displays only ~20 and ~50% sequence identity with NK-1R and MrgprB2, respectively. Despite this difference, NK-1R, MrgprB2 and MRGPRX2 are all responsive to SP and the tripeptide NK-1R antagonist (QWF) blocks SP responses to all three receptors [17]. These findings suggest that all three receptors possess specific binding sites for both SP and QWF. Site directed mutagenesis studies of NK-1R demonstrated that amino acid residues 23-25 (NQF) in the receptor's amino terminus along with H¹⁰⁸ (third transmembrane domain), F²⁶⁸ (sixth transmembrane domain) and Y²⁸⁷ (7th transmembrane domain) are important for binding substance P [56-58]. Furthermore, histidine at position 197 (H¹⁹⁷) in the fifth transmembrane helix of human NK-1R binds specifically to the non-peptide receptor antagonist CP 96345 to block SP action [59]. Thus, identification of SP and QWF binding sites on MRGPRX2 may provide useful information for the development of MRGPRX2-specific antagonists.

Acknowledgement

This work was supported by NIH grants R21-AI108585 and R01-AI124182. I thank Kshitij Gupta, Ph.D. for careful review of this manuscript.

References

1. Subramanian H, Gupta K, Ali H (2016) Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. *J Allergy Clin Immunol* 138: 700-710.
2. Gurish MF, Austen KF (2012) Developmental origin and functional specialization of mast cell subsets. *Immunity* 37: 25-33.
3. Irani AM, Bradford TR, Kepley CL, Schechter NM, Schwartz LB (1989) Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and antichymase antibodies. *J Histochem Cytochem* 37: 1509-1515.
4. Oskeritzian CA, Zhao W, Min HK, Xia HZ, Pozez A, et al. (2005) Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell. *J Allergy Clin Immunol* 115: 1162-1168.
5. Fukuoka Y, Xia HZ, Sanchez-Munoz LB, Dellinger AL, Escribano L, et al. (2008) Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5. *J Immunol* 180: 6307-6316.
6. Ruitenber EJ, Elgersma A (1976) Absence of intestinal mast cell response in congenitally athymic mice during *Trichinella spiralis* infection. *Nature* 264: 258-260.
7. Manning BM, Gruba SM, Meyer AF, Haynes CL (2016) Neuropeptide-induced mast cell degranulation and characterization of signaling modulation in response to IgE conditioning. *ACS Chem Biol* 11: 3077-3083.
8. van der Kleij HP, Ma D, Redegeld FA, Kraneveld AD, Nijkamp FP, et al. (2003) Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. *J Immunol* 171: 2074-2079.
9. Lotts T, Stander S (2014) Research in practice: substance P antagonism in chronic pruritus. *J Dtsch Dermatol Ges* 12: 557-559.
10. Remrod C, Lonne-Rahm S, Nordlind K (2007) Study of substance P and its receptor neurokinin-1 in psoriasis and their relation to chronic stress and pruritus. *Arch Dermatol Res* 299: 85-91.
11. O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, et al. (2004) The role of substance P in inflammatory disease. *J Cell Physiol* 201: 167-180.
12. Hossen MA, Inoue T, Shinmei Y, Fujii Y, Watanabe T, et al. (2006) Role of substance P on histamine H3 antagonist-induced scratching behavior in mice. *J Pharmacol Sci* 100: 297-302.
13. Hens G, Raap U, Vanoirbeek J, Meyts I, Callebaut I, et al. (2011) Selective nasal allergen provocation induces substance P-mediated bronchial hyperresponsiveness. *Am J Respir Cell Mol Biol* 44: 517-523.
14. Boot JD, de Haas S, Tarasevych S, Roy C, Wang L, et al. (2007) Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. *Am J Respir Crit Care Med* 175: 450-457.
15. Rost K, Fleischer F, Nieber K (2006) Neurokinin 1 receptor antagonists--between hope and disappointment. *Med Monatsschr Pharm* 29: 200-205.
16. Quartara L, Altamura M, Evangelista S, Maggi CA (2009) Tachykinin receptor antagonists in clinical trials. *Expert Opin Investig Drugs* 18: 1843-1864.
17. Azimi E, Reddy VB, Shade KC, Anthony RM, Talbot S, et al. (2016) Dual action of neurokinin-1 antagonists on Mas-related GPCRs. *JCI Insight* 1: e89362.
18. Matsuda H, Kawakita K, Kiso Y, Nakano T, Kitamura Y (1989) Substance P induces granulocyte infiltration through degranulation of mast cells. *J Immunol* 142: 927-931.
19. Yano H, Wershil BK, Arizono N, Galli SJ (1989) Substance P-induced augmentation of cutaneous vascular permeability and granulocyte infiltration in mice is mast cell dependent. *J Clin Invest* 84: 1276-1286.
20. Zhang Y, Lu L, Furlonger C, Wu GE, Paige CJ (2000) Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. *Nat Immunol* 1: 392-397.
21. Sumpter TL, Ho CH, Pleet AR, Tkacheva OA, Shufesky WJ, et al. (2015) Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses. *J Allergy Clin Immunol* 135: 1019-1030.
22. Nakae S, Ho LH, Yu M, Monteforte R, Iikura M, et al. (2007) Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice. *J Allergy Clin Immunol* 120: 48-55.
23. Nakae S, Lunderius C, Ho LH, Schafer B, Tsai M, et al. (2007) TNF can contribute to multiple features of ovalbumin-induced allergic inflammation of the airways in mice. *J Allergy Clin Immunol* 119: 680-686.
24. Nakae S, Suto H, Berry GJ, Galli SJ (2007) Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. *Blood* 109: 3640-3648.
25. McNeil BD, Pundir P, Meeker S, Han L, Udem BJ, et al. (2015) Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. *Nature* 519: 237-241.
26. Gaudenzio N, Sibilano R, Marichal T, Starkl P, Reber LL, et al. (2016) Different activation signals induce distinct mast cell degranulation strategies. *J Clin Invest* 126: 3981-3998.
27. Nieber K, Baumgarten CR, Rathsack R, Furkert J, Oehme P, et al. (1992) Substance P and β -endorphin-like immunoreactivity in lavage fluids of subjects with and without allergic asthma. *J Allergy Clin Immunol* 90: 646-652.
28. Tomaki M, Ichinose M, Miura M, Hirayama Y, Yamauchi H, et al. (1995) Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. *Am J Respir Crit Care Med* 151: 613-617.
29. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP (2008) Neuropeptides activate human mast cell degranulation and chemokine production. *Immunology* 123: 398-410.
30. Fujisawa D, Kashiwakura J, Kita H, Kikukawa Y, Fujitani Y, et al. (2014) Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. *J Allergy Clin Immunol* 134: 622-633.
31. Tatemoto K, Nozaki Y, Tsuda R, Konno S, Tomura K, et al. (2006) Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. *Biochem Biophys Res Commun* 349: 1322-1328.
32. Subramanian H, Kashem SW, Collington SJ, Qu H, Lambris JD, et al. (2011) PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells. *Mol Pharmacol* 79: 1005-1013.

33. Sabroe RA, Poon E, Orchard GE, Lane D, Francis DM, et al. (1999) Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcεRI or anti-IgE autoantibodies. *J Allergy Clin Immunol* 103: 484-493.
34. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, et al. (2002) Mast-cell infiltration of airway smooth muscle in asthma. *N Engl J Med* 346: 1699-1705.
35. Page S, Ammit AJ, Black JL, Armour CL (2001) Human mast cell and airway smooth muscle cell interactions: implications for asthma. *Am J Physiol Lung Cell Mol Physiol* 281: 1313-1323.
36. Robinson DS (2004) The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? *J Allergy Clin Immunol* 114: 58-65.
37. Kajiura N, Sasaki T, Bradding P, Cruse G, Sagara H, et al. (2010) Activation of human mast cells through the platelet-activating factor receptor. *J Allergy Clin Immunol* 125: 1137-1145.
38. Fajt ML, Gelhaus SL, Freeman B, Uvalle CE, Trudeau JB, et al. (2013) Prostaglandin D2 pathway upregulation: relation to asthma severity, control, and TH2 inflammation. *J Allergy Clin Immunol* 131: 1504-1512.
39. Balzar S, Fajt ML, Comhair SA, Erzurum SC, Bleeker E, et al. (2011) Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. *Am J Respir Crit Care Med* 183: 299-309.
40. van Diest SA, Stanisor OI, Boeckxstaens GE, de Jonge WJ, van den Wijngaard RM (2012) Relevance of mast cell-nerve interactions in intestinal nociception. *Biochim Biophys Acta* 1822: 74-84.
41. Heaney LG, Cross LJ, Stanford CF, Ennis M (1995) Substance P induces histamine release from human pulmonary mast cells. *Clin Exp Allergy* 25: 179-186.
42. Riese RJ, Mitchell RN, Villadangos JA, Shi GP, Palmer JT, et al. (1998) Cathepsin S activity regulates antigen presentation and immunity. *J Clin Invest* 101: 2351-2363.
43. Zhou PP, Zhang WY, Li ZF, Chen YR, Kang XC, et al. (2016) Association between SNPs in the promoter region in cathepsin S and risk of asthma in Chinese Han population. *Eur Rev Med Pharmacol Sci* 20: 2070-2076.
44. Deschamps K, Cromlish W, Weicker S, Lamontagne S, Huszar SL, et al. (2011) Genetic and pharmacological evaluation of cathepsin s in a mouse model of asthma. *Am J Respir Cell Mol Biol* 45: 81-87.
45. Reddy VB, Sun S, Azimi E, Elmariah SB, Dong X, et al. (2015) Redefining the concept of protease-activated receptors: cathepsin S evokes itch via activation of Mrgpr. *Nat Commun* 6: 7864.
46. Busse WW, Gern JE, Dick EC (1997) The role of respiratory viruses in asthma. *Ciba Found Symp* 206: 208-213.
47. Calhoun WJ, Swenson CA, Dick EC, Schwartz LB, Lemanske RF, et al. (1991) Experimental rhinovirus 16 infection potentiates histamine release after antigen bronchoprovocation in allergic subjects. *Am Rev Respir Dis* 144: 1267-1273.
48. Zhu J, Message SD, Qiu Y, Mallia P, Kebabze T, et al. (2014) Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma. *Chest* 145: 1219-1229.
49. Rohde G, Message SD, Haas JJ, Kebabze T, Parker H, et al. (2014) CXC-chemokines and antimicrobial peptides in rhinovirus-induced experimental asthma exacerbations. *Clin Exp Allergy* 44: 930-939.
50. Duits LA, Nibbering PH, van Strijen E, Vos JB (2003) Mannese-Lazeroms SP, van Sterkenburg MA, Hiemstra PS: Rhinovirus increases human β-defensin-2 and -3 mRNA expression in cultured bronchial epithelial cells. *FEMS Immunol Med Microbiol* 38: 59-64.
51. Proud D, Sanders SP, Wiehler S (2004) Human rhinovirus infection induces airway epithelial cell production of human β-defensin 2 both in vitro and in vivo. *J Immunol* 172: 4637-4645.
52. Subramanian H, Gupta K, Guo Q, Price R, Ali H (2011) Mas-related gene X2 (MrgX2) is a novel G protein-coupled receptor for the antimicrobial peptide LL-37 in human mast cells: resistance to receptor phosphorylation, desensitization, and internalization. *J Biol Chem* 286: 44739-44749.
53. Subramanian H, Gupta K, Lee D, Bayir AK, Ahn H, et al. (2013) β-Defensins activate human mast cells via Mas-related gene X2. *J Immunol* 191: 345-352.
54. Gupta K, Subramanian H, Ali H (2016) Modulation of host defense peptide-mediated human mast cell activation by LPS. *Innate Immun* 22: 21-30.
55. Hagiwara D, Miyake H, Morimoto H, Murai M, Fujii T, et al. (1992) Studies on neurokinin antagonists. 1. The design of novel tripeptides possessing the glutamyl-D-tryptophylphenylalanine sequence as substance P antagonists. *J Med Chem* 35: 2015-2025.
56. Fong TM, Yu H, Huang RR, Strader CD (1992) The extracellular domain of the neurokinin-1 receptor is required for high-affinity binding of peptides. *Biochemistry* 31: 11806-11811.
57. Fong TM, Huang RR, Yu H, Strader CD (1993) Mapping the ligand binding site of the NK-1 receptor. *Regul Pept* 46: 43-48.
58. Valentin-Hansen L, Park M, Huber T, Grunbeck A, Naganathan S, et al. (2014) Mapping substance P binding sites on the neurokinin-1 receptor using genetic incorporation of a photoreactive amino acid. *J Biol Chem* 289: 18045-18054.
59. Fong TM, Cascieri MA, Yu H, Bansal A, Swain C, et al. (1993) Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345. *Nature* 1993 362: 350-353.